Johna Spertus News Today

NIH-supported findings identify risk factors in women and suggest the need for closer monitoring. A study funded by the National Institutes of Health shows that women aged 55 and younger are nearly twice as likely to be rehospitalized within a year of a heart attack compared to men of the same ag

/PRNewswire/ -- A new study published in JAMA[1] demonstrated that patients at high risk for acute kidney injury (AKI), the most common complication of...

For the approximately 8.5 million people in the U.S. living with peripheral artery disease (PAD – pronounced P-A-D), which is narrowed or clogged arteries in

Statement Highlights: A new American Heart Association scientific statement provides an updated roadmap for incorporating patient-reported symptoms and quality of life assessments into routine care for people with peripheral artery disease (PAD or ...

Treatment with Aficamten Associated with Significant Improvements in Symptoms and Quality of Life Additional Data Presented in Poster Session Shows...

Nonadherence prevents patients from achieving treatment benefits, but it also complicates trial interpretation, suggests subanalyses of MASTER DAPT and ISCHEMIA.

Two analyses of large randomized controlled trials suggest that participants not taking medications as prescribed may influence treatment effects and impact study findings, researchers reported.In analyses assessing medication nonadherence for the ISCHEMIA and MASTER DAPT trials, researchers found that the detrimental effect of nonadherence — worse health status — was consistent among

ACC late-breaking phase 3 data from EXPLORER-HCM trial on first-in-class cardiac myosin inhibitor

Posted on 1113 Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70 th Annual Scientific Session (ACC.21), with simultaneous publication in The Lancet. At 30 weeks, th...

New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient’s health status to be presented as late-breaking oral presentation Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy also to be presented Bristol Myers Squibb today announced that data from multiple studies across the company’s clinical … New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient...